Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6596754

Cc1cc(COc2ccc(C(=O)NC3(CC(=O)NO)CCC3)cc2)c2ccccc2n1.O=C(O)C(F)(F)F

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 19/20 0.86
ADAMTS4 O75173 2/20 0.78
MMP3 P08254 2/20 0.78
MMP7 P09237 2/20 0.78
ADAMTS1 Q9UHI8 2/20 0.78
ADAMTS5 Q9UNA0 2/20 0.78
MMP8 P22894 1/20 0.78
MMP13 P45452 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6594927 0.98 ADAM17 (0.89) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6596361 0.98 ADAM17 (0.91) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6598804 0.98 ADAM17 (0.91) ADAM17ADAMTS4MMP3MMP7ADAMTS1
SCHEMBL6600065 0.95 ADAM17 (0.95) ADAM17ADAMTS4MMP3MMP7ADAMTS1
SCHEMBL6595027 0.93 ADAM17 (0.98) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6599941 0.93 ADAM17 (0.85) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6594483 0.93 ADAM17 (0.77) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6598115 0.93 ADAM17 (0.91) ADAM17ADAMTS4MMP3MMP7ADAMTS1
Trifluoroacetic Acid SCHEMBL6596034 0.93 ADAM17 (0.86) ADAM17ADAMTS4MMP3MMP7ADAMTS1
SCHEMBL6597320 0.93 ADAM17 (1.00) ADAM17ADAMTS4MMP3MMP7ADAMTS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040072802-A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha DUAN JINGWU (US) 2004-04-15 US disclosed
EP-1263756-B1 BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA BRISTOL MYERS SQUIBB PHARMA CO (US) 2004-02-25 EP disclosed
US-6495565-B2 FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-12-17 US disclosed
EP-1263756-A2 BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA Bristol-Myers Squibb Pharma Company (US) 2002-12-11 EP disclosed
US-20020013341-A1 Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-01-31 US disclosed
WO-2001070734-A2 BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072802-A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha TNF, XPNPEP1, MMP2 ADAM17 29/4885ADAMTS4 68/4885MMP3 12/4885
US-20020013341-A1 Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha TNF, XPNPEP1, MMP2 ADAM17 27/4885ADAMTS4 61/4885MMP3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.